Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.4MCash on Hand
2.7mo Cash Runway
Follow CVKD by emailGet an email when CVKD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CVKD, unsubscribe in one click. Privacy
📣 What CVKD Says Is Next
in 2029 · “Planned pivotal Phase 3 study, the first randomized, blinded, placebo-controlled registration trial in HIT, will evaluate CAD-1005 in approximately 120 patients across clinical centers worldwide and is intended to support a projected NDA submission in 2029.”
Company press release, May 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 7, 2026 ·
Deal Cadrenal's board authorized a formal strategic process to evaluate options to maximize portfolio value, including licensing, asset sales, partnerships or business combinations. The company retained Tungsten Advisors as exclusive advisor and set no deadline; there is no assurance of any transaction. Form 8-K · SEC filing · Press release
Sep 29, 2026 ·
Shareholder vote Stockholders approved raising the 2022 equity plan's share reserve by 323,542 shares to 1,000,000 and approved issuing up to 960,000 shares on Series C-1 warrant exercises. Quang X. Pham was re-elected as a Class I director. Form 8-K · SEC filing
Aug 31, 2026 ·
Regulatory Cadrenal reported positive FDA Type D meeting feedback on the Phase 3 registrational study of CAD-1005 for heparin-induced thrombocytopenia, including agreement on an optimized primary endpoint and use of a placebo control with standard anticoagulation in both arms. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings Reported Q2 2026 net loss of $3.3 million, down from $3.7 million a year earlier, and about $4.2 million in cash as of early August, expected to fund operations through Q1 2027. Launched a partnering process for CAD-1005, frunexian and tecarfarin. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
CVKD holds $2.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations,
an estimated runway of 2.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:100 · High
Cash runway 3 months +40
ATM program on file since Dec 2025 +15
Shelf registration (S-3, Mar 2024) +10
Going-concern doubt in the latest 10-Q +15These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued.10-Q, Nov 2026
Share count 4,122,081 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CVKD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CVKD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.